Editas Medicine

Q2 FY2026 EarningsQ2 FY26 results were significantly above consensus, with revenue of $11.89M beating the $2.75M estimate due to accelerated BMS collaboration revenue recognition. GAAP EPS of -$0.15 exceeded the -$0.27 mean expectation, driven by lower-than-expected operating expenses following a major workforce reduction. A May 2026 public offering strengthened the balance sheet to $211.6M in cash, extending the runway into 2028.